Burford Capital’s (BUR) extended rebuttal of Muddy Waters’ short-selling note continues today, with an extended chronology of its investment in Napo Pharmaceuticals’ litigation against Salix Pharmaceuticals. One of the litigation funder’s earliest investments, the case has been the subject of investor inquiries following what Burford describes as “inaccurate and misleading” reporting by Muddy Waters. The group also said it plans to “provide a further presentation on other accounting and disclosure matters” in a forthcoming update, news which appears to have pushed the shares higher in early trading.
Login or register to post comments